Skip Navigation
 

Translational Research Unit (TRU)

Clinical Trials

Clinical trials, also called research studies, are managed by government agencies, educational institutions, private not-for-profit organizations, or commercial businesses, to develop, produce, and evaluate the effectiveness of new treatments and therapies for diseases. New trials are added on a routine basis, and many clinical trials accept only a limited number of participants. MUSC participates in a large number of clinical trials. If you are interested in treatment for a specific condition, search our neurosciences clinical trial list below, or visit the other clinical trials databases to review your options.


Clinical Trials Databases


MUSC Neurosciences Clinical Trials

Neuro-Oncology

RTOG 1205: Randomized, Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Investigator: Scott Lindhorst, MD
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

ALLIANCE A071401: Phase II Trial of SMO/NF2 Inhibitors in Progressive Meningiomas With SMO/NF2 Mutations
Investigator: Scott Lindhorst, MD
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

ALLIANCE A071102: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Investigator: Scott Lindhorst, MD
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

ICT 107-301: A Phase III Randomized Double-Blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Investigator: Scott Lindhorst, MD
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

ABBVIE M13-813/RTOG 3508: A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification
Investigator: David Cachia, MD
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

TOCAGEN Tg 511-15-01: A Phase 2/3 Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Investigator: David Cachia, MD
Coordinator: Michele DeCandio, RN, OCN, CCRP (843-792-9016, decandio@musc.edu)

DVT Risk Factors In High Grade Glioma
Investigator: David Cachia, MD
Coordinator: Christine Hudson (843-792-3790, hudsoncm@musc.edu)

 

Alzhiemers

ENGAGE 221AD301: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease
Investigator: David Clark, MD
Coordinator: Bo Keller, CCRP (843-792-2209, kellej@musc.edu)

 

Movement Disorders

K-23: Identification of Gait and Imaging Markers for Freezing of Gait in Parkinson’s Disease
Investigator: Gonzalo Revuelta, MD 
Coordinator: Shonna Jenkins (843-792-9115,  jenkisho@musc.edu)

Boston Scientific INTREPID: Implantable Neurostimulator for the Treatment of Parkinson’s Disease
Investigator: Gonzalo Revuelta, MD                         
Coordinator: Tracy Millman (843-792-8311,  millmant@musc.edu)

Validation of Parkinson’s Disease Motor Scale via Tele-Neurology: Remote Assessments of Patients with Parkinson’s Disease in South Carolina via Tele-Neurology: Validation of the New Movement Disorder Society (MDS)-Unified Parkinson’s Disease Rating Scale
Investigator: Christina Vaughan, MD                        
Coordinator: Shonna Jenkins (843-792-9115,  jenkisho@musc.edu)

Light Reflex in PD: Validation of a smart phone application to measure pupillary light reflex in untreated Parkinson patients and healthy adults
Investigator: Jenna Renfroe                         
Coordinator: Shonna Jenkins (843-792-9115,  jenkisho@musc.edu)

SD-809-C-23: A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose Study of SD-809 (Deutetrabenazine) for the Treatment for Moderate to Severe Tardive Dyskinesia
Investigator: Christina Vaughan, MD
Coordinator: Nancy Feracco, RN (843-792-7859,  feracco@musc.edu)

SD-809-C-20: An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Investigator: Christine Vaughan, MD
Coordinator: Nancy Feracco, RN (843-792-7859, feracco@musc.edu)

CVT-301-004: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients with Motor Response Fluctuations (OFF Phenomena)
Investigator: Vanessa Hinson, MD
Coordinator: Nancy Feracco, RN (843-792-7859, feracco@musc.edu)

CVT-301-004E: A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients with Motor Response Fluctuations (OFF Phenomena)
Investigator: Vanessa Hinson, MD
Coordinator: Nancy Feracco, RN (843-792-7859, feracco@musc.edu)

SYNAPSE: SYN120, A Dual 5-HT6/5-HT2A Antagonist Proff of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia
Investigator: Vanessa Hinson, MD
Coordinator: Nancy Feracco, RN (843-792-7859, feracco@musc.edu)


Epilepsy

The Human Epilepsy Project
Investigator: Jonathan Halford, MD                          
Coordinator: Becky Hamrick (843-792-3855, hamrickr@musc.edu)

GWEP1414: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in children and adults
Investigator: Jonathan Halford, MD                          
Coordinator: Becky Hamrick (843-792-3855, hamrickr@musc.edu)

GWEP1424: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults with Dravet Syndrome
Investigator: Jonathan Halford, MD                          
Coordinator: Becky Hamrick (843-792-3855, hamrickr@musc.edu)

ACORDA DZNS-EP-1025: An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults with Cluster Seizures
Investigator: Jonathan Halford, MD                          
Coordinator: Becky Hamrick (843-792-3855, hamrickr@musc.edu)

NIH-2R44NS064647-05A1: High Performance Seizure Monitoring and Alert System – Phase IIB
Investigator: Jonathan Halford, MD
Coordinator: Christine Hudson (843-792-3790,  hudsoncm@musc.edu)

APHASIA: Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes
Investigator: Leo Bonhila, MD                                   
Coordinator: Aparna Choudhury (843-792-2845, choudhur@musc.edu)

fMRI in Anterior Temporal Epilepsy Surgery
Investigator: Leo Bonhila, MD                                   
Coordinator: Aparna Choudhury (843-792-2845, choudhur@musc.edu)

SAGE-547-SSE-301: A Randomized, Double-Blind, Placebo-Controlled Study TO Evaluate The Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects with Super-Refractory Status Epilepticus
Investigator: Jonathan Halford, MD
Coordinator: Bo Keller (843-792-2209,  kellej@musc.edu)

 

Spine

VTI: A Prosepective Study of the VTI Interfuse T™
Investigator: Steve Kalhorn, MD
Coordinator: Christine Hudson (843-792-3309,  hudsoncm@musc.edu)

 

Useful links

 
 
 

© 2012  Medical University of South Carolina | Disclaimer | Contact the Webmaster